STANDARTIZATION OF IMMUNOGENICITY OF INACTIVATED VACCINE QAZVAC AGAINST CORONAVIRUS INFECTION COVID-19 FROM AN EPIDEMIOLOGICALLY RELEVANT STRAIN
Main Article Content
Authors
B.Sh. Myrzakhmetova
Research Institute for Biological Safety Problems, Guardeyskiy uts. Republic of Kazakhstan
G.A. Zhapparova
Research Institute for Biological Safety Problems, Guardeyskiy uts. Republic of Kazakhstan
K.B. Bissenbayeva
Research Institute for Biological Safety Problems, Guardeyskiy uts. Republic of Kazakhstan
A.S. Toytanova
Research Institute for Biological Safety Problems, Guardeyskiy uts. Republic of Kazakhstan
M.S. Tuyskanova
Research Institute for Biological Safety Problems, Guardeyskiy uts. Republic of Kazakhstan
G.D. Nakhanova
Research Institute for Biological Safety Problems, Guardeyskiy uts. Republic of Kazakhstan
S.Sh. Nurabayev
Research Institute for Biological Safety Problems, Guardeyskiy uts. Republic of Kazakhstan
K.D. Zhugunissov
Research Institute for Biological Safety Problems, Guardeyskiy uts. Republic of Kazakhstan
L.B. Kutumbetov
Research Institute for Biological Safety Problems, Guardeyskiy uts. Republic of Kazakhstan
Abstract
This article presents the results of studies on the standardization of the immunogenicity of the domestic QazVac vaccine using different methods to recommend the available ones for use in laboratories that do not require special biological protection. The immunogenicity of the vaccine was assessed by specific antibodies to the SARS-CoV-2 virus, for the detection of which a neutralization reaction and ELISA method were used. Syrian hamsters were taken as model animals. Commercial kits produced by ID-Vet, France, JSC VECTOR-BEST, Russia, as well as experimental samples of the kit manufactured at the Research Institute of Biochemical Biochemistry were used as ELISA test systems. The results obtained showed that in Syrian hamsters vaccinated with the vaccine, from the 14th day of observation, specific virus-neutralizing antibodies to the SARS-CoV-2 virus were detected in the neutralization reaction in 100% of cases.
Keywords
vaccines, strain, immunogenicity, standartization, mutation, neutralization
Article Details
References
Pachetti M., Marini B., Benedetti F., Giudici F., Mauro E., Storici P., Masciovecchio C., Angeletti S. et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. Journal of Translational Medicine. - 2020. - Vol.18, N 179. -P. 1-9. Crossref
Zhang L., Jackson C.B., Mou H. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. - 2020. - Vol.11, N 6013. - P.1-9. Crossref
Spruth M, Kistner O, Savidis-Dacho H, Hitter E, Crowe B, et al. A
double-inactivated whole virus candidate SARS coronavirus vaccine stimulates
neutralizing and protective antibody responses. Vaccine. - 2006. - Vol. 24, N 5. - P. 652 - 661. Crossref
Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G, Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Liu M., Xiao Y., Gao H., Guo L., Xie J. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China // The Lancet. - 2020. - Vol. 15, N 395(10223). - P. 497-506. Crossref
Jin Y, Yang H, Ji W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses. - 2020. - Vol. 12, N 372. -P.1-17. Crossref.
URL. org/hcov19-variants. Relative Variant Genome Frequency per Region.
URL. int/ru/news/item/classification-of-omicron-(b.1.1.529)- sars-cov-2-variant-of-concern.
Forchette L. A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics / L. Forchette, W. Sebastian, T. Liu // Curr Med Sci. - 2021. - Vol. 41, N 6. - P. 1037-1051. Crossref 021-2395-1.
Torjesen I. COVID‐19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ. - 2021. - Vol. 375, N 2943. Crossref.
Nyberg T., Ferguson N.M., Nash S.G., et al. Comparative analysis of the risks of hospitalisation and death associated with SARSCoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. The Lancet. - 2022. - Vol. 399, N 2. - P.1303-1312. Crossref S0140-6736(22)00462-7.
Araf Y., Akter F., Tang Y.D., et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. - 2022. - Vol. 94, N 5. - P.1825-1832. Crossref jmv.27588.
Chen Y., Shen H., Huang R., Tong X., Wu C. Serum neutralizing activity against SARS CoV-2 variants elicited by CoronaVac. Lancet Infect Dis. - 2021. - Vol. 21, N 8. - P.1071-1072. Crossref
Sapkal G.N., Yadav P.D., Ella R. et al. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2. J. Travel Med. - 2022. - Vol. 28, N 4. - P.1-7. Crossref
Novikova I. A. Genetic characteristics of the SARS-CoV-2 virus / I. A. Novikova // Living and bioinert systems. - 2021. - N 35. Crossref 9709-2021-35-4
Samoilov A., Kaptelova V.V., Bukharina A.Y., Shipulina O.Y., Korneenko E.V., Saenko S.S., Lukyanov A.V., et al. Case report: change of dominant strain during dual SARS-CoV-2 infection. BMC Infect. Dis. - 2021. - Vol. 21, N 959. - P.1-8. Crossref
Fu Y., Zhao J., Wei X., Han P., Yang L., Ren T., Zhan S., Li L. Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence from Randomized Control Trials and Real-World Studies. // Front Public Health. - 2022. - Vol.10, N 917732. - P.1-11. Crossref.
Shiliaev N., Lukash T., Palchevska O., Crossman D.K., Green T.J., Crowley M.R., Frolova E.I., Frolov I. Natural and recombinant SARS-CoV-2 isolates rapidly evolve in vitro to higher infectivity through more efficient binding to heparan sulfate and reduced S1/S2 cleavage. J. Virol., - 2021. - Vol. 95, N 21. Crossref
Myrzakhmetova B.Sh., Bissenbayeva K.B., Kaukarbaeva M.Zh., Burashev E.D., Kutumbetov L.B. Cultural properties of the South African Omicron variant of the SARS-CoV-2 coronavirus infection COVID-19. Scientific journal Biosafety and Biotechnology. - 2022. N 12. - С.36-43. Crossref
Garg R., Gautam P., Suroliya V., Agarwal R., Bhugra A., Kaur U.S. et al. Evidence of early community transmission of Omicron (B1.1.529) in Delhi. Trav Med Infect Dis. - 2022. - Vol.46. Crossref 2276
Wilhelm A., Widera M., Grikscheit K., Toptan T., Schenk B., Pallas C. et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. eBioMedicine. - 2022. - Vol.04, N 58. - P.1-9. Crossref
Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., Müller M.A., Drosten C., Pöhlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. - 2020. - Vol. 181, N 2. - P.271-280. Crossref 10.1016/j.cell.2020.02.052
Logunov D.Y., Dolzhikova I.V., Zubkova O.V., Tukhvatullin A.I., Shcheblyakov D.V., Dzharullaeva A.S., Grousova D.M., Erokhova A.S., Kovyrshina A.V., Botikov A.G., Izhaeva F.M., Popova O., Ozharovskaya T.A., Esmagambetov I.B., Favorskaya I.A., Zrelkin D.I., Voronina D.V., Shcherbinin D.N., Semikhin A.S., Simakova Y.V., Tokarskaya E.A., Lubenets N.L., Egorova D.A., Shmarov M.M., Nikitenko N.A., Morozova L.F., Smolyarchuk E.A., Kryukov E.V., Babira V.F., Borisevich S.V., Naroditsky B.S., Gintsburg A.L. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. - 2020. - Vol. 396, N. 10255. - P.887-897. Crossref
Jennewein M.F., MacCamy A.J., Akins N.R., Feng J., Homad L.J., Hurlburt N.K., Seydoux E., Wan Y.H., Stuart A.B., Edara V.V., Floyd K., Vanderheiden A., Mascola J.R., Doria-Rose N., Wang L., Yang E.S., Chu H.Y., Torres J.L., Ozorowski G., Ward A.B., Whaley R.E., Cohen K.W., Pancera M., McElrath M.J., Englund J.A., Finzi A., Suthar M.S., McGuire A.T., Stamatatos L. Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19 subjects. Cell Rep. - 2021. - Vol. 36, N. 2. Crossref
Rashidi F., Simbar M. Corona-virus pandemic and worries during pregnancy. Arch. Acad. Emerg. Med. - 2020. - Vol.8, N.1. Crossref
Analytical regulatory document (AND) for quality control of the inactivated vaccine QazCOVID-in (QazVac). - Guardeyskiy. - 2021. - 354 p.
Reed L.J., Muench Simple H. A. Method Of Estimating Fifty Per Cent Endpoints12 //American Journal of Epidemiology. - 1938. - Vol. 27, - P. 493-497. Crossref
Nurpeisova A., Khairullin B., Abitaev R., Shorayeva K., Jekebekov K., Kalimolda E., Kerimbayev A., Akylbayeva K., Abay Zh., Myrzakhmetova B., Nakhanov A., Absatova Zh., Nurabayev S., Orynbayev M., Assanzhanova N., Abeuov Kh., Kutumbetov L., Kassenov M., Abduraimov Y., Zakarya K. Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19. Human Vaccines and Immuno-therapeutics. - 2022. - Vol.18, N.5. Crossref
Zhugunissov K, Zakarya K, Khairullin B, Orynbayev M, Abduraimov Y, Kassenov M, Sultankulova K, Kerimbayev A, Nurabayev S, Myrzakhmetova B, Nakhanov A, Nurpeisova A, Chervyakova O, Assanzhanova N, Burashev Y, Mambetaliyev M, Azanbekova M, Kopeyev S, Kozhabergenov N, Issabek A, Tuyskanova M, Kutumbetov L. Development of the Inactivated QazCovid-in Vaccine: Protective Efficacy of the Vaccine in Syrian Hamsters. // Front Microbiol. - 2021. - Vol.27, N.12. Crossref
Zakarya K, Kutumbetov L, Orynbayev M, Abduraimov Y, Sultankulova K, Kassenov M, Sarsenbayeva G, Kulmagambetov I, Davlyatshin T, Sergeeva M, Stukova M, Khairullin B. Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan. // EClinicalMedicine. - 2021. N.39. P.1-11. Crossref
Khairullin B., Zakarya K., Orynbayev M., Abduraimov Y., Kassenov M., Sarsenbayeva G., Sultankulova K., Chervyakova O., Myrzakhmetova B., Nakhanov A., Nurpeisova A., Zhugunissov K., Assanzhanova N., Nurabayev S., Kerimbayev A., Yershebulov Z., Burashev Y., Kulmagambetov I., Davlyatshin T., Kutumbetov L. Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up. EClinicalMedicine. - 2022. - Vol. 50, N.101526. Crossref
Fu Y, Zhao J, Wei X, Han P, Yang L, Ren T, Zhan S, Li L. Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies. // Front Public Health. - 2022. N.10:917732. Crossref